Donepezilo Almus (Donepezil Hydrochloride)

Donepezilo Almus is indicated for the symptomatic treatment of mild to moderate Alzheimer’s disease, helping to improve cognitive function and daily activities. It may also be considered in clinical practice for related neurodegenerative conditions when approved by a healthcare professional.

• Improves memory and attention in patients with Alzheimer’s disease.
• Supports daily functioning and orientation.
• May be used as part of a comprehensive dementia management plan.
• Typically prescribed after a confirmed diagnosis of Alzheimer’s disease.
• May be combined with non‑pharmacologic therapies for optimal benefit.

Donepezilo Almus can cause a range of side effects, most of which are mild and transient, while some may require medical attention.

Common

• Nausea, vomiting, or loss of appetite.
• Diarrhea or abdominal cramps.
• Insomnia or vivid dreams.
• Muscle cramps or fatigue.
• Headache.

Serious

• Severe bradycardia or heart block.
• Gastrointestinal bleeding.
• Seizures or convulsions.

Before starting Donepezilo Almus, patients should discuss their medical history and current health status with a healthcare provider to ensure safe use.

• Assess cardiac history, especially bradyarrhythmias.
• Review liver function, as hepatic impairment may affect metabolism.
• Caution in patients with a history of gastrointestinal ulcers or bleeding.
• Monitor for signs of severe nausea, vomiting, or weight loss.
• Use carefully in individuals with epilepsy or seizure disorders.

Donepezilo Almus may interact with other medications, altering its effectiveness or increasing the risk of adverse effects. Review all concurrent drugs with a healthcare professional.

Avoid

• Strong anticholinergic agents (e.g., diphenhydramine) that may counteract its action.
• Non‑selective beta‑blockers that can exacerbate bradycardia.
• Certain anti‑arrhythmic drugs (e.g., quinidine).

Use with caution

• Other cholinesterase inhibitors or cholinergic agents.
• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) which may increase plasma levels.
• NSAIDs or anticoagulants that raise bleeding risk.